Remove tag aav
article thumbnail

Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy

XTalks

million price tag of Elevidys, a one-time gene therapy. The progression of DMD is often rapid, and those affected usually face a significantly shortened lifespan with severe physical limitations. Options for managing the symptoms of DMD have been limited. In a media call, Sarepta CEO Douglas Ingram revealed the $3.2

article thumbnail

Bluebird’s $2.8M Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia

XTalks

Zynteglo’s hefty price tag of $2.8 What’s happening to them is not unique to bluebird,” said Nicole Paulk, an assistant professor of AAV gene therapy at the University of California, San Francisco in a Biopharma Dive report. The cells are prepared outside of the body ( ex vivo ) and then infused into the patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche’s Luxturna and Novartis’ Zolgensma. The case comes just weeks after UniQure halted a trial of its haemophilia B gene therapy AMT-061 after an unexpected case of liver cancer.

article thumbnail

Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA

XTalks

Zolgensma is an adeno-associated virus vector (AAV)-based gene therapy that delivers a functional copy of the SMN1 gene into target motor neurons to replace the mutant copy. With a price tag of over $2.5 million, Zolgensma is currently the world’s most expensive drug. Why is Zolgensma So Expensive?

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite the limited market, the price tags of haemophilia make it potentially lucrative. Haemophilia B is a rare condition.

article thumbnail

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Delveinsight

It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. Shinya Yamanaka discovered that the factors could alter the epigenome, and in that way modify mature cells back to a stem cell-like state.

article thumbnail

Roctavian okay sets up another gene therapy test for Europe

pharmaphorum

Roctavian delivers a working copy of the Factor VIII gene into cells via an adeno-associated virus (AAV) vector, and offers a one-shot, potentially curative therapy for haemophilia A. million spread over five years.